ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CCR8 Monoclonal Antibody HC006

Its studies are led by HC Biopharma.

Furthest: phase 1, since Mar 5, 20242 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HC Biopharma22 open or runningphase 1since Mar 5, 2024Mar 5, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2024First study: phase 1 study in Advanced Solid TumorFirst studyNCT06304571 · 76 planned · China
  2. Apr 30, 2025Phase 1 study in Advanced CancerNCT06963814 · 252 planned · China

TargetBeta

CCR8 →read by rule
“A monoclonal antibody directed against human C-C motif chemokine receptor 8 (CCR8), ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
denikitugruleGilead Sciencesphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
azirkitugAbbViephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06963814Advanced Cancer · China1RecruitingMay 30, 2026252
NCT06304571Advanced Solid Tumor · China1RecruitingMar 15, 202676

How it is read

Names in the registry

  • “HC006”, 2 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.